A phase III trial of epitinib in first-line patients with EGFR-mutant NSCLC patients with brain metastasis
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Epitinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Chi-Med
- 06 Mar 2018 According to a Chi-Med media release, the company is preparing to initiate this pivotal study of epitinib in EGFR mutant NSCLC patients with brain metastasis in China in 2018.
- 18 Aug 2016 New trial record
- 02 Aug 2016 According to Chi-Med media release, company targets to initiate this pivotal registration study before the end of H1 2017.